Medivir AB continues to make significant progress in its preparations for the planned phase 2b study of fostrox in combination with Lenvima. Following a successful Type C meeting with the FDA, the company remains on track to initiate the study as scheduled. The positive outcome of the meeting was further reinforced by the latest data, which showed that the median time to progression with fostrox + Lenvima increased to an impressive 7 months.
This encouraging development highlights the potential of Medivir’s innovative approach to treating advanced cancers. By combining fostrox with the well-established Lenvima, the company aims to provide patients with a more effective treatment option that can significantly extend the time to disease progression. As Medivir continues to advance its pipeline, the upcoming phase 2b study will be a critical milestone in the development of this promising combination therapy.